Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315313 | 0.94 | MAPT (0.41) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6313897 | 0.93 | KDM1A (0.38) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6323423 | 0.93 | KDM1A (0.38) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6314117 | 0.91 | KDM1A (0.37) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6314453 | 0.90 | MAPT (0.43) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6315331 | 0.87 | MAPT (0.38) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6315408 | 0.87 | MAPT (0.38) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6316452 | 0.87 | MAPT (0.39) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6322855 | 0.87 | MAPT (0.39) | KDM1AMAPTKDM4ELMNANPSR1 | |
| SCHEMBL6316373 | 0.85 | MAPT (0.37) | KDM1AMAPTKDM4ELMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | KDM1A 1764/4885MAPT 4538/4885KDM4E 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.